222 related articles for article (PubMed ID: 31758731)
1. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
[TBL] [Abstract][Full Text] [Related]
2. High throughput thermostability screening of monoclonal antibody formulations.
He F; Hogan S; Latypov RF; Narhi LO; Razinkov VI
J Pharm Sci; 2010 Apr; 99(4):1707-20. PubMed ID: 19780136
[TBL] [Abstract][Full Text] [Related]
3. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
[TBL] [Abstract][Full Text] [Related]
4. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
[TBL] [Abstract][Full Text] [Related]
5. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
6. Development of a high-throughput solubility screening assay for use in antibody discovery.
Chai Q; Shih J; Weldon C; Phan S; Jones BE
MAbs; 2019; 11(4):747-756. PubMed ID: 30913963
[TBL] [Abstract][Full Text] [Related]
7. High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody.
Niedziela-Majka A; Kan E; Weissburg P; Mehra U; Sellers S; Sakowicz R
J Biomol Screen; 2015 Apr; 20(4):552-9. PubMed ID: 25385011
[TBL] [Abstract][Full Text] [Related]
8. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
9. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
10. Sorbitol crystallization-induced aggregation in frozen mAb formulations.
Piedmonte DM; Hair A; Baker P; Brych L; Nagapudi K; Lin H; Cao W; Hershenson S; Ratnaswamy G
J Pharm Sci; 2015 Feb; 104(2):686-97. PubMed ID: 25219372
[TBL] [Abstract][Full Text] [Related]
11. Isothermal chemical denaturation as a complementary tool to overcome limitations of thermal differential scanning fluorimetry in predicting physical stability of protein formulations.
Svilenov H; Markoja U; Winter G
Eur J Pharm Biopharm; 2018 Apr; 125():106-113. PubMed ID: 29329817
[TBL] [Abstract][Full Text] [Related]
12. An application of Nano Differential Scanning Fluorimetry for Higher Order Structure assessment between mAb originator and biosimilars: Trastuzumab and Rituximab as case studies.
Joshi S; Maharana C; Rathore AS
J Pharm Biomed Anal; 2020 Jul; 186():113270. PubMed ID: 32380351
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
14. Thermofluor-based optimization strategy for the stabilization and crystallization of Campylobacter jejuni desulforubrerythrin.
Santos SP; Bandeiras TM; Pinto AF; Teixeira M; Carrondo MA; Romão CV
Protein Expr Purif; 2012 Feb; 81(2):193-200. PubMed ID: 22051151
[TBL] [Abstract][Full Text] [Related]
15. The effect of arginine glutamate on the stability of monoclonal antibodies in solution.
Kheddo P; Tracka M; Armer J; Dearman RJ; Uddin S; van der Walle CF; Golovanov AP
Int J Pharm; 2014 Oct; 473(1-2):126-33. PubMed ID: 24992318
[TBL] [Abstract][Full Text] [Related]
16. Predicting Colloidal Stability of High-Concentration Monoclonal Antibody Formulations in Common Pharmaceutical Buffers Using Improved Polyethylene Glycol Induced Protein Precipitation Assay.
Meza NP; Hardy CA; Morin KH; Huang C; Raghava S; Song J; Zhang J; Wang Y
Mol Pharm; 2023 Nov; 20(11):5842-5855. PubMed ID: 37867303
[TBL] [Abstract][Full Text] [Related]
17. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody.
Menzen T; Friess W
J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634
[TBL] [Abstract][Full Text] [Related]
18. Russell body phenotype is preferentially induced by IgG mAb clones with high intrinsic condensation propensity: relations between the biosynthetic events in the ER and solution behaviors in vitro.
Hasegawa H; Woods CE; Kinderman F; He F; Lim AC
MAbs; 2014; 6(6):1518-32. PubMed ID: 25484054
[TBL] [Abstract][Full Text] [Related]
19. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.
Neergaard MS; Kalonia DS; Parshad H; Nielsen AD; Møller EH; van de Weert M
Eur J Pharm Sci; 2013 Jun; 49(3):400-10. PubMed ID: 23624326
[TBL] [Abstract][Full Text] [Related]
20. Thermodynamic Unfolding and Aggregation Fingerprints of Monoclonal Antibodies Using Thermal Profiling.
Melien R; Garidel P; Hinderberger D; Blech M
Pharm Res; 2020 Apr; 37(4):78. PubMed ID: 32236701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
